SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Wilson Wolf, an innovative leader in cell and gene-modified cell (CGT) manufacturing technology, today announced a collaboration around the automation of Wilson Wolf’s G-Rex® bioreactors..

旧金山--（商业新闻短讯）--Multiply Labs是一家开发行业领先的自动化制造系统以生产个性化药物的机器人公司，Wilson Wolf是细胞和基因修饰细胞（CGT）制造技术的创新领导者，今天宣布围绕Wilson Wolf的G-Rex®生物反应器的自动化进行合作。。

This collaboration is intended to provide the CGT field with easy-to-use high throughput ballroom manufacturing that reduces the need for highly skilled labor. The ultimate goal is to lower the barriers to widespread accessibility of potentially lifesaving cell and gene therapy drug products.

此次合作旨在为CGT领域提供易于使用的高通量宴会厅制造，减少对高技能劳动力的需求。最终目标是降低潜在救生细胞和基因治疗药物产品广泛可及性的障碍。

G-Rex® closed system bioreactors simplify CGT manufacturing by providing cells with unlimited oxygen and nutrients on demand. Without the need for media or oxygen pumps, G-Rex® bioreactors function as an all-in-one stand-alone activation, transduction, expansion, and concentration device. This unique attribute is ideal for high throughput automated movement of G-Rex® bioreactors in a ballroom setting and for standardizing much of the CGT manufacturing process..

G-Rex®封闭系统生物反应器通过按需为细胞提供无限的氧气和营养物质，简化了CGT的制造。不需要介质或氧气泵，G-Rex®生物反应器可以作为一个一体的独立激活、转导、扩增和浓缩装置。这种独特的特性非常适合在舞厅环境中高通量自动移动G-Rex®生物反应器，以及标准化大部分CGT制造过程。。

“With G-Rex® making several commercial drug products, producing cells for nearly 50% of CGT clinical trials, and now becoming widely accepted as an all-in-one device, it’s time to apply automation selectively and thoughtfully. Automation doesn’t need to be complicated or unique to the field of cell and gene therapy.

“随着G-Rex®生产多种商业药物产品，为近50%的CGT临床试验生产细胞，并且现在已被广泛接受为一体式设备，是时候有选择地、深思熟虑地应用自动化了。自动化不需要复杂或独特于细胞和基因治疗领域。

The simplicity of G-Rex® allows us to implement the type of automation solutions that occur millions of times a day in a wide variety of mature industries,” said John Wilson, CEO of Wilson Wolf Corporation. 'Multiply Labs has been working independently with G-Rex® for several years and has exceptional experience in automation, so collaborating on our mutual goal of further cost reducing, simplifying, and standardizing CGT manufacturing is a good way to gain additional traction.”.

威尔逊·沃尔夫公司（Wilson Wolf Corporation）首席执行官约翰·威尔逊（JohnWilson）表示：“G-Rex®的简单性使我们能够实现各种成熟行业每天数百万次的自动化解决方案。”Multiply Labs多年来一直与G-Rex®独立合作，在自动化方面拥有非凡的经验，因此就进一步降低成本、简化和标准化CGT制造的共同目标进行合作是获得额外吸引力的好方法。”。

'Our ongoing objective is to develop a seamlessly automated, plug-and-play solution for cell therapy manufacturing automation, aiming to lower labor costs, enhance output, and expand access of these critical therapies to a greater number of patients than ever before,' said Fred Parietti, Ph.D., Co-Founder and CEO of Multiply Labs.

Multiply Labs联合创始人兼首席执行官弗雷德·帕里蒂（FredParietti）博士说：“我们目前的目标是为细胞疗法生产自动化开发一种无缝自动化的即插即用解决方案，旨在降低劳动力成本，提高产量，并将这些关键疗法的使用范围扩大到比以往任何时候都更多的患者。”。

'Our partnership with Wilson Wolf will be pivotal in realizing this future, as their G-Rex® bioreactors are extensively used for cell therapy manufacturing today. This means manufacturers can use the automated G-Rex® bioreactor without substantially changing their existing process.'.

“我们与威尔逊·沃尔夫（Wilson Wolf）的合作关系对于实现这一未来至关重要，因为他们的G-Rex®生物反应器如今已广泛用于细胞治疗制造。这意味着制造商可以使用自动G-Rex®生物反应器，而无需大幅改变其现有工艺。”。

Cytotherapy, the journal of the International Society for Cell & Gene Therapy (ISCT), recently published a first-of-its-kind peer-reviewed article on Multiply Labs’ proof-of-concept robotic system developed with leading cell therapy organizations. It found that Multiply Labs’ robotic system can automate T cell-based therapy expansion without compromising critical process parameters.

国际细胞与基因治疗学会（ISCT）杂志《细胞疗法》（Cytotherapy）最近发表了首篇同类同行评审文章，内容涉及Multiple Labs与领先细胞治疗组织合作开发的概念验证机器人系统。研究发现，Multiply Labs的机器人系统可以在不影响关键工艺参数的情况下自动化基于T细胞的治疗扩展。

Industry estimates suggest this technology could cut typical GMP-level cell therapy manufacturing costs by around 70% per product..

行业估计表明，这项技术可以将典型的GMP级细胞疗法生产成本每种产品降低约70%。。

About Multiply Labs

关于Multiply Labs

Multiply Labs is a robotics company that provides autonomous manufacturing technology to the pharmaceutical industry. The company develops advanced, cloud-controlled robotic systems that enable the production of individualized drugs at scale. Its customers include some of the largest global organizations in the advanced pharmaceutical manufacturing space.

Multiply Labs是一家机器人公司，为制药行业提供自主制造技术。该公司开发了先进的云控制机器人系统，可以大规模生产个性化药物。其客户包括先进制药制造领域的一些最大的全球组织。

Multiply Labs’ expertise is at the intersection of robotics and biopharma – its team includes mechanical engineers, electrical engineers, computer scientists, software engineers and pharmaceutical scientists. The founding team got in touch because of their shared love of robots at MIT. The company is based in San Francisco, California.

Multiply Labs的专业知识是机器人技术和生物制药的交叉点，其团队包括机械工程师、电气工程师、计算机科学家、软件工程师和制药科学家。创始团队之所以取得联系，是因为他们在麻省理工学院共同热爱机器人。该公司总部位于加利福尼亚州旧金山。

For more information, please visit www.multiplylabs.com..

有关更多信息，请访问www.multiplylabs.com。。

About Wilson Wolf Corporation

关于Wilson Wolf Corporation

Wilson Wolf Corporation (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production..

威尔逊·沃尔夫公司（www.wilsonwolf.com）致力于简化细胞和基因修饰细胞（CGT）治疗研究、工艺开发和制造。这是通过其可扩展的G-Rex®技术实现的，该技术在全球范围内用于CGT应用，从基础研究到商业药物生产。。

Wilson Wolf’s mission is to create hope for cancer patients, one G-Rex® device at a time.

威尔逊·沃尔夫（Wilson Wolf）的使命是为癌症患者创造希望，一次一个G-Rex®设备。